ArticleArchives of osteoporosis2025
Trends in the incidence of hip fractures and osteoporosis treatment in Japan (FY2012-FY2023).
Article in Archives of osteoporosis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although the number of patients with hip fracture increased till FY2017, it remained stable over the next 3 years, possibly owing to enhanced treatment rates and changed medications. However, the number of patients with hip fracture again increased FY2021 onwards, coinciding with the COVID-19 pandemic. PURPOSE: To clarify the trends in hip fracture incidence and its relationship with pre-fracture pharmacotherapy over time in Japan.
methodsUsing Japan's National Database of Health Insurance Claims and Specific Health Checkups, we examined the number of patients with hip fracture and their osteoporosis medication status from fiscal year (FY) 2012 to FY2023.
resultsA total of 1,636,198 females and 460,898 males had hip fractures. The crude number of patients in FY2020 was 181,443, indicating a decrease of 654 from the previous year. The number of patients per 10,000 females decreased in FY2018 and FY2020 compared with the previous year. The osteoporosis medication rate in the year before the fracture was 33.5%-34.3% for females from FY2013 to FY2019, but it was significantly decreased to 32.4%-32.9% from FY2020 to FY2023 (p < 0.01). The pre-fracture medication rate was significantly related to the number of patients per 10,000 population (p < 0.05). Bisphosphonates were the most common drug administered after 2015. Denosumab, romosozumab, and eldecalcitol tended to increase over time.
conclusionAlthough the number of patients with hip fractures increased until FY2017, it remained stagnant over the next 3 years, possibly due to enhanced treatment rates and changed medications. However, the number of patients with hip fractures again increased from FY2021 onwards, coinciding with the coronavirus disease 2019 (COVID-19) pandemic in Japan. Post-COVID-19, increasing adherence to effective osteoporosis medications may curb or even reduce the number of patients with hip fractures.
Indexed as
Identifiers
41417146What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.